| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| Targets |
p65
|
|---|---|
| ln Vitro |
The concentrations of TNF-α and IL-6 in the supernatant of cells pretreated with 2.5 or 25 mg/L of Schisantherin A are significantly decreased compared to the LPS control group (p<0.05, p<0.01). The MTT assay is used to assess the potential cytotoxicity of Schisantherin A after cells are incubated for 24 hours in the presence or absence of LPS. The results show that the cytokines do not affect cell viability at the used concentrations (0.5, 2.5, and 25 mg/L). Schisantherin A is pre-incubated for 1 hour with RAW 264.7 murine macrophage cells before stimulation with 1 mg/L LPS is applied for 12 hours. In the control group, neither LPS nor the samples are treated. Schisantherin A is found to reduce NO and PGE2 production in a dose-dependent manner after the cell culture media are collected, nitrite levels, and PGE2 levels are assessed[1].
|
| ln Vivo |
Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera, has been reported to have a variety of positive pharmacological effects. Schisantherin A prevents lipopolysaccharide-induced acute respiratory distress syndrome in mice by blocking the NF-κB and MAPK signaling pathways. Pretreatment with Schisantherin A significantly lessens the histopathologic changes brought on by LPS and lowers the levels of TNF-α, IL-6, and IL-1β in the BALF. Additionally, Schisantherin A inhibits the phosphorylation of NF-κB p65, IκB-α, JNK, ERK and p38 induced by LPS. At 7 hours following the intranasal administration of LPS, the lung wet/dry weight ratio is assessed. Schisantherin A (40 mg/kg) and the control groups did not differ in any way, according to the results (p>0.05). In comparison to the control group, LPS significantly increases the lung wet/dry weight ratio (p<0.01). Compared to those in the LPS group, schistantherin A dose-dependently lowers the lung wet/dry weight ratio (p<0.05)[1].
|
| Cell Assay |
Cell viability is assessed using the MTT assay. RAW 264. Mechanically scraped 7 cells are seeded at a density of 4×105 cells per mL in 96-well plates, and they are then incubated in a 37 °C, 5% CO2 incubator over night. Cells are stimulated with 50 μL LPS for 18 h after being exposed to different concentrations of Schisantherin A (0–25 mg/L) for 50 μL for 1 h. The cells are then incubated for 4 hours after 20 μL of 5 mg/mL MTT in FBS-free medium is added to each well. 150 L of DMSO per well is used to dissolve MTT. Using a microplate reader, the optical density at 570 nm is calculated. This triplicate experiment measures concentrations in three wells of each sample[1].
|
| Animal Protocol |
Mice: Male BALB/c mice, 6-8 weeks old, are used. The six groups consist of the control group, the Schisantherin A (40 mg/kg) group, the LPS group, the Schisantherin A (10, 20 and 40 mg/kg)+LPS group, and the Dexamethasone (DEX)+LPS group. A positive control is the DEX+LPS group. Intraperitoneally administered Schisantherin A and DEX (5 mg/kg). A comparable amount of PBS is administered to the mice in the control and LPS groups. In order to cause lung damage, mice are given 10 g of LPS in 50 μL of PBS an hour after being given a light anesthetic (diethyl ether) inhalation. Instead of LPS, 50 L of PBS are given to control mice. Following a 7-hour LPS treatment, all mice are still alive[1].
|
| References |
|
| Molecular Formula |
C30H32O9
|
|---|---|
| Molecular Weight |
536.57
|
| Exact Mass |
536.2046
|
| Elemental Analysis |
C, 67.15; H, 6.01; O, 26.84
|
| CAS # |
58546-56-8
|
| Related CAS # |
58546-56-8
|
| Appearance |
Solid powder
|
| SMILES |
C[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4[C@@H]([C@@]1(C)O)OC(=O)C5=CC=CC=C5)OC)OC)OC)OC)OCO3
|
| InChi Key |
UFCGDBKFOKKVAC-DSASHONVSA-N
|
| InChi Code |
InChI=1S/C30H32O9/c1-16-12-18-13-21-25(38-15-37-21)26(35-5)22(18)23-19(14-20(33-3)24(34-4)27(23)36-6)28(30(16,2)32)39-29(31)17-10-8-7-9-11-17/h7-11,13-14,16,28,32H,12,15H2,1-6H3/t16-,28-,30-/m0/s1
|
| Chemical Name |
[(8S,9S,10S)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] benzoate
|
| Synonyms |
Gomisin C; Schisantherin A
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~186.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8637 mL | 9.3184 mL | 18.6369 mL | |
| 5 mM | 0.3727 mL | 1.8637 mL | 3.7274 mL | |
| 10 mM | 0.1864 mL | 0.9318 mL | 1.8637 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
